Aubagio Alternatives Compared
Aubagio (teriflunomide) | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
---|
Aubagio (teriflunomide) | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Aubagio is a selective immunosuppressant that may be used in the treatment of multiple sclerosis. It interacts with many other medications and carries a boxed warning about the risk of liver toxicity... View more |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Copaxone is a combination of four amino acids that may be given to treat relapsing forms of multiple sclerosis in adults. It has been shown to significantly reduce the number of relapses but may be... View more |
Related suggestions |
|||||||||||||||||||||||
More about Aubagio (teriflunomide) | More about Kesimpta (ofatumumab) | More about Copaxone (glatiramer) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Aubagio has an average rating of 5.4 out of 10 from a total of 86 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 38% reported a negative effect. |
Kesimpta has an average rating of 6.9 out of 10 from a total of 72 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 18% reported a negative effect. |
Copaxone has an average rating of 7.6 out of 10 from a total of 133 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 16% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Aubagio prices |
View all Kesimpta prices |
View all Copaxone prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
Other ofatumumab brands include: Arzerra | Other glatiramer brands include: Glatopa | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
456 hours |
1476 hours |
1 hour |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 732 drugs are known to interact with Aubagio:
|
A total of 172 drugs are known to interact with Kesimpta:
|
A total of 1 drugs are known to interact with Copaxone:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
September 12, 2012 |
N/A |
December 20, 1996 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.